Priority Research Areas for Neurodegenerative Disease R&D

Migration, Crosslink

📖

Priority Research Areas for Neurodegenerative Disease R&D

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-investment-priority-research-areas

📖 Wiki Page

investment1256 wordssynced 2026-04-02

Executive Summary

Overview

flowchart TD investment_priority_research_a["Priority Research Areas for Neurodegenerative Di"] style investment_priority_research_a fill:#4fc3f7,stroke:#333,color:#000 investment_priority__0["Executive Summary"] investment_priority_research_a -->|"includes"| investment_priority__0 style investment_priority__0 fill:#81c784,stroke:#333,color:#000 investment_priority__1["Cross-Disease Gap Analysis"] investment_priority_research_a -->|"includes"| investment_priority__1 style investment_priority__1 fill:#ef5350,stroke:#333,color:#000 investment_priority__2["Clinical Trial Portfolio Metrics"] investment_priority_research_a -->|"includes"| investment_priority__2 style investment_priority__2 fill:#ffd54f,stroke:#333,color:#000 investment_priority__3["Critical Gaps Identified"] investment_priority_research_a -->|"includes"| investment_priority__3 style investment_priority__3 fill:#ce93d8,stroke:#333,color:#000 investment_priority__4["Priority Area 1: Combination Therapies"] investment_priority_research_a -->|"includes"| investment_priority__4 style investment_priority__4 fill:#4fc3f7,stroke:#333,color:#000 investment_priority__5["Rationale"] investment_priority_research_a -->|"includes"| investment_priority__5 style investment_priority__5 fill:#81c784,stroke:#333,color:#000

...

Executive Summary

Overview

Mermaid diagram (expand to render)

This page identifies priority research areas for neurodegenerative disease R&D, focusing on therapeutic targets, mechanistic pathways, and strategic investment opportunities. The analysis considers disease burden, scientific tractability, and commercial potential.

This page identifies priority research areas based on gap analysis of the current clinical trial landscape across neurodegenerative diseases. Analysis of [ClinicalTrials.gov](https://clinicaltrials.gov) data reveals significant unmet needs and investment opportunities. [@clinicaltrialsgov2026]

Cross-Disease Gap Analysis

Clinical Trial Portfolio Metrics

| Disease | Total Trials | Active Trials | Late-Stage (Phase 3/4) | Biomarker Programs | Investment Landscape |
|---|---|---|---|---|---|
| [Alzheimer's Disease](/diseases/alzheimers-disease) | 4,910 | 1,208 (24.6%) | 489 (10.0%) | 453 (9.2%) | [View](/investment/alzheimers) |
| [Parkinson's Disease](/diseases/parkinsons-disease) | 4,613 | 1,061 (23.0%) | 437 (9.5%) | 254 (5.5%) | [View](/investment/parkinsons) |
| [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) | 1,569 | 434 (27.7%) | 91 (5.8%) | 124 (7.9%) | [View](/investment/als) |
| [Frontotemporal Dementia](/diseases/frontotemporal-dementia) | 380 | 124 (32.6%) | 20 (5.3%) | ~30 (7.9%) | [View](/investment/ftd) |
| [Huntington's Disease](/diseases/huntingtons) | 285 | 66 (23.2%) | 25 (8.8%) | ~20 (7.0%) | [View](/investment/huntingtons) |

Data refreshed: 2026-03-17

Critical Gaps Identified

Low Late-Stage Representation: Phase 3/4 trials represent only 5-10% of total pipeline

Minimal Combination Therapy: 0% combination-therapy signals across major diseases

Biomarker Deficiency: Only 5-9% of trials incorporate biomarker endpoints

Rare Disease Underfunding: MSA, PSP, CBD, and Huntington's have <300 trials each

ALS Funding Gap: Only 91 Phase 3 trials for a uniformly fatal disease

Priority Area 1: Combination Therapies

Rationale

The complete absence of combination-therapy signals in major neurodegenerative disease trials represents a critical gap. Given the multifactorial nature of these diseases, addressing multiple pathological mechanisms simultaneously is likely necessary for disease modification. [@combination2024]

Recommended Approaches

Amyloid + Tau Combination: Sequential or simultaneous targeting of [amyloid-beta](/proteins/amyloid-beta) and tau pathology
Neuroinflammation Modulation: Combining anti-amyloid or anti-synuclein approaches with microglial modulators
Mitochondrial + Protein Aggregation: Dual targeting of mitochondrial dysfunction and protein aggregation
Synaptic Protection + Disease Modification: Combining neuroprotective agents with disease-modifying therapies

Research Priorities

Phase 2 combination-safety studies for approved monoclonal antibodies

Repurposing existing drugs for combination approaches

Biomarker-driven patient stratification for combination trials

Priority Area 2: Enhanced Biomarker Integration

Rationale

Only 5-9% of current trials incorporate biomarker endpoints, limiting the ability to demonstrate biological activity and select responsive patient populations. [@bloodbased2025]

Recommended Biomarker Focus Areas

Fluid Biomarkers: CSF and blood-based tau, amyloid, [alpha-synuclein](/proteins/alpha-synuclein), [NfL](/biomarkers/neurofilament-light-chain-nfl)
Imaging Biomarkers: PET tracers for tau, amyloid, synaptic density
Digital Biomarkers: wearable-based motor and cognitive monitoring

Research Priorities

Validate fluid biomarker assays for patient selection

Develop blood-based biomarker tests for widespread screening

Establish biomarker-endpoint correlations across disease stages

Priority Area 3: Rare Neurodegenerative Diseases

Rationale

[Multiple System Atrophy](/diseases/multiple-system-atrophy) (MSA), [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) (CBD), and [Huntington's disease](/diseases/huntington-disease) collectively affect ~100,000-200,000 patients in the US but have minimal trial activity. [@rare2024]

Current Trial Activity

| Disease | Estimated US Prevalence | Active Trials |
|---|---|---:|
| Huntington's Disease | ~30,000 | 66 |
| MSA | ~50,000 | ~30 |
| PSP | ~20,000 | ~25 |
| CBD | ~5,000 | ~15 |

Research Priorities

Huntington's Disease: Focus on gene-silencing approaches (ASO, RNAi) and mitochondrial protectors

MSA/PSP/CBD: Develop alpha-synuclein aggregation inhibitors and neuroprotective agents

Patient Registry Development: Build natural history databases to support trial design

Priority Area 4: [Parkinson's](/diseases/parkinsons-disease) Disease - Non-Motor Symptoms

Rationale

[Parkinson's](/diseases/parkinsons-disease) disease has robust motor symptom coverage but significant gaps in non-motor symptom therapeutics, which often have greater impact on quality of life. [@parkinsons2024]

Unmet Needs

Cognitive Impairment/Dementia: No approved therapies
Psychiatric Symptoms: Depression, anxiety, psychosis
Autonomic Dysfunction: Orthostatic hypotension, gastrointestinal issues
Sleep Disorders: REM behavior disorder, insomnia

Research Priorities

Alpha-synuclein targeting for cognitive decline prevention

Novel neurotransmitter modulators for psychiatric symptoms

Device-assisted therapies for autonomic dysfunction

Priority Area 5: Disease Modification in ALS

Rationale

ALS has the lowest late-stage representation (5.8%) and smallest overall pipeline, despite being uniformly fatal with median survival of 2-5 years. [@als2025]

Current Challenges

Only 91 Phase 3 trials total (5.8% of pipeline)
Highest unmet need across all neurodegenerative diseases
Limited therapeutic options beyond riluzole and edaravone

Research Priorities

SOD1 and [C9orf72](/entities/c9orf72) Targeting: Continue and expand gene-specific approaches

[TDP-43](/mechanisms/tdp-43-proteinopathy) Pathology: Develop therapies addressing TDP-43 aggregation

Metabolic/Mitochondrial Approaches: Energy metabolism support

Combination Strategies: Multi-target approaches given disease heterogeneity

Priority Area 6: Neuroinflammation as a Therapeutic Target

Rationale

Neuroinflammation is a common feature across all neurodegenerative diseases but remains undertargeted in clinical trials. [@neuroinflammation2024]

Therapeutic Approaches

Microglial Modulation: [TREM2](/proteins/trem2) agonists, colony-stimulating factor 1 receptor (CSF1R) antagonists
[NLRP3 Inflammasome](/entities/nlrp3-inflammasome) Inhibition: Small molecule inhibitors
[Complement System](/entities/complement-system) Modulation: C1q and C3 inhibitors
Pro-Resolving Mediators: SPMs and specialized pro-resolving mediators

Research Priorities

Biomarker development for neuroinflammation selection

Timing interventions - prophylactic vs. symptomatic

Combination with disease-modifying agents

Priority Area 7: Genetic Risk Factor Targeting

Rationale

Genetic forms of neurodegenerative diseases offer well-validated targets with clear mechanisms. [@genetic2025]

Priority Targets

| Gene | Associated Diseases | Therapeutic Approach |
|---|---|---|
| GBA1 | [Parkinson's](/diseases/parkinsons-disease), Lewy Body Dementia | Gene augmentation, enzyme enhancement |
| LRRK2 | [Parkinson's](/diseases/parkinsons-disease) | Kinase inhibitors, gene silencing |
| SNCA | [Parkinson's](/diseases/parkinsons-disease), MSA | Alpha-synuclein aggregation inhibitors, gene silencing |
| [MAPT](/proteins/tau) | FTD, Alzheimer's | Tau aggregation inhibitors |
| C9orf72 | ALS, FTD | Gene silencing, dipeptide repeat inhibitors |
| [HTT](/proteins/huntingtin) | Huntington's | ASO, RNAi gene silencing |

Research Priorities

Continue gene-specific clinical programs

Develop population-specific genetic therapies

Explore heterozygous dosing for dominant-negative mutations

Implementation Framework

Immediate Actions (0-12 months)

Establish Combination Therapy Working Group: Bring together sponsors, academics, and regulators

Biomarker Validation Consortia: Multi-stakeholder biomarker development

Rare Disease Trial Networks: Build infrastructure for rare neurodegenerative disease trials

Medium-Term Goals (1-3 years)

First Combination Therapy Trials: Initiate Phase 2 combination studies

Biomarker-Enabled Trial Platforms: Adaptive trials with biomarker stratification

Expanded Genetic Screening: Broaden genetic testing in clinical practice

Long-Term Vision (3-5 years)

Precision Medicine Frameworks: Genotype and biomarker-driven treatment selection

Disease-Modifying Combination Standards: Establish standard-of-care combinations

Prevention Trials: Initiate trials in pre-symptomatic genetic carriers

Conclusion

The neurodegenerative disease R&D landscape shows significant gaps in combination therapies, biomarker integration, rare disease research, and non-motor symptom treatment. Addressing these priorities requires coordinated effort across academic, industry, and regulatory stakeholders. The highest-impact investments in the near term would be:

Combination therapy safety and efficacy studies

Biomarker validation and integration

Rare disease trial infrastructure

ALS Phase 3 trial acceleration (only 91 trials for a fatal disease)

Neuroinflammation-targeted therapeutics

Clinical Trials

For current clinical trials across neurodegenerative diseases, see:

[Clinical Trials Index](/clinical-trials)
[Clinical Trials: Alzheimer's Disease](/clinical-trials/alzheimers-disease)
[Clinical Trials: Parkinson's Disease](/clinical-trials/parkinsons-disease)

References

ClinicalTrials.gov Neurodegenerative Disease Pipeline Analysis (2026) (2026)

[Combination Therapy Approaches in Alzheimer's Disease - Nature Reviews Drug Discovery (2024) (2024)](https://doi.org/10.1038/s41573-024-00800-2))

[Blood-Based Biomarkers for Neurodegenerative Diseases - Acta Neuropathologica (2025) (2025)](https://doi.org/10.1007/s00401-025-00345-x))

[Rare Neurodegenerative Disease Epidemiology - Orphanet Journal of Rare Diseases (2024) (2024)](https://doi.org/10.1186/s13023-024-03100-5))

[Parkinson's Disease Non-Motor Symptoms - Lancet Neurology (2024) (2024)](https://doi.org/10.1016/S1474-4422(24))

[ALS Clinical Trials Landscape - Nature Reviews Neurology (2025) (2025)](https://doi.org/10.1038/s41582-025-00900-4))

[Neuroinflammation in Neurodegeneration - Neuron (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.06.015))

[Genetic Forms of Neurodegenerative Diseases - Brain (2025) (2025)](https://doi.org/10.1093/brain/awae180))

📖 View canonical wiki page →

Related Entities

investment-priority-research-areas

▸Metadataorigin_type: v1_polymorphic_backfill

slug	investment-priority-research-areas
kg_node_id	None
entity_type	investment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0f98fad788ab
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'investment-priority-research-areas'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

29

Outgoing

42

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Priority Research Areas for Neurodegenerative Disease R&D

Executive Summary

Overview

Executive Summary

Overview

Cross-Disease Gap Analysis

Clinical Trial Portfolio Metrics

Critical Gaps Identified

Priority Area 1: Combination Therapies

Rationale

Recommended Approaches

Research Priorities

Priority Area 2: Enhanced Biomarker Integration

Rationale

Recommended Biomarker Focus Areas

Research Priorities

Priority Area 3: Rare Neurodegenerative Diseases

Rationale

Current Trial Activity

Research Priorities

Priority Area 4: [Parkinson's](/diseases/parkinsons-disease) Disease - Non-Motor Symptoms

Rationale

Unmet Needs

Research Priorities

Priority Area 5: Disease Modification in ALS

Rationale

Current Challenges

Research Priorities

Priority Area 6: Neuroinflammation as a Therapeutic Target

Rationale

Therapeutic Approaches

Research Priorities

Priority Area 7: Genetic Risk Factor Targeting

Rationale

Priority Targets

Research Priorities

Implementation Framework

Immediate Actions (0-12 months)

Medium-Term Goals (1-3 years)

Long-Term Vision (3-5 years)

Conclusion

Clinical Trials

See Also

References

💬 Discussion